
"LFMD: Telehealth co growing 20% revenue despite semaglutide headwinds from choosing $500 Wegovy vs $150 generics. Medicare approval for 21M Americans drove app downloads 400→900/day but revenue flat Q/Q. Management guides flat through 2025 but expects all weightloss customers covered by insurance/cheaper options by year-end. At 1.2x P/S vs prior 5x, return to growth could drive $40 price target by 2027."
Is it better to ask forgiveness than permission? LifeMD $LFMD (Update)
Unemployed Value Degen
September 2, 2025
Stock Idea